A Phase 3 interventional study of Bifocal Spectacles and Single Vision Lenses in Esotropia, sponsored by Jaeb Center for Health Research. Withdrawn. Open to participants aged 3 Years to 9 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment
Compare the proportion of BFL and SVL participants with treatment failure by 36 months, compare binocular function test scores between the BFL and SVL groups with both groups in BFL at 38 months after randomization (or 2 months after treatment failure), and evaluate treatment failure by 36 months according to baseline factor subgroups of: duration of constant esotropia pre-enrollment, presence of near stereoacuity on the Randot Preschool Stereoacuity test, in-office response of near alignment with +3.00 D lenses, and gradient AC/A ratio
Participants will be randomly assigned to treatment with a BFL or SVL spectacle correction for 3 years. Generally, participants will be followed at 3-month intervals for the first year and every 6 months thereafter until the primary outcome visit at 36 months. At each follow-up visit between 3 months and 36 months, ocular alignment and stereoacuity will be assessed to determine if any of the three study-specified failure criteria have been met (worsening of distance esotropia (ET), reduction in near stereoacuity, or frequent diplopia ("more than 2 times per day" over the last week). The primary outcome is failure at or before 36 months.
If a failure criterion is met between 3 to 30 months, participants randomized to SVLs will be prescribed BFLs and those in BFLs will be prescribed continued BFLs. Participants in both groups will return in BFLs 2 months after failure for a Post-failure Secondary Outcome Visit to determine the child's binocular function, after which the child will be released to treatment at investigator discretion. Participants with confirmed failure who complete the Post-failure Secondary Outcome Exam will return for the 12- and 24-month follow-up visits (abbreviated testing) as well as the 38-month Secondary Outcome Visit (they will not return for the 36-month Primary Outcome visit).
If a failure criterion is not met between 3 to 30 months, participants without confirmed failure will complete the 36-month Primary Outcome Visit, After the 36-month visit, SVL group participants will be prescribed BFLs and BFL participants will continue using BFLs.
All participants (i.e., regardless of failure status) will return for a 38-month Secondary Outcome Visit to assess binocular function.
33 studies on the registry are indexed under Esotropia; 10 are open to participants now.
Browse Esotropia studies →Jaeb Center for Health Research is the lead sponsor of 126 studies on the registry; 17 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Esodeviation meeting all the following criteria is present in refractive correction (if required or worn)
Distance esotropia (constant, intermittent), esophoria, or orthophoria, with near esodeviation ≥10∆ larger than distance deviation by PACT
Spectacles (if worn) must meet the following criteria:
Best-corrected VA meeting the following criteria:
Exclusion Criteria:
Device: Single Vision Lenses
Device: Bifocal Spectacles
Bifocals with a +3.00 Diopter flat top 35
Single vision lens as prescribed by provider
Number of Participants meeting treatment failure at any follow up visit before 36 months
Failure criteria can be described as 1. Distance motor failure: Constant ET ≥15∆ by simultaneous prism and cover test (SPCT) at distance. 2. Near stereo failure: Decrease in near stereoacuity on the Randot Preschool Stereotest of 2 or more levels from baseline or from 960" at baseline to nil (criteria not applicable if nil near stereo at baseline) 3. Binocular diplopia with a frequency of "more than 2 times per day" over the last week by parental report 4. Nonsurgical or surgical treatment for ET, other than the randomized treatment, is started before a failure criterion is met
Time frame: 36 months
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research